Review
Aug 2026
Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.
Current evidence supports strong biological efficacy, but definitive proof of clinical benefit awaits ongoing randomized cardiovascular outcomes trials, including Lp(a)HORIZON (pelacarsen), OCEAN(a)-Outcomes (olpasiran) and ACCLAIM-Lp(a) (lepodisiran).
José Pablo Miramontes González
· American Journal of Cardiova... · 0 citations